Research Papers:
Silencing PPA1 inhibits human epithelial ovarian cancer metastasis by suppressing the Wnt/βcatenin signaling pathway
PDF | Full Text | Supplementary Files | How to cite
Metrics: PDF 2307 views | Full Text 3845 views
Haiying Niu1,*, Wei Zhou2,*, Yingxi Xu3, Zhiqi Yin4, Wenzhi Shen2, Zhen Ye2, Yanhua Liu2, Yanan Chen2, Shuang Yang2, Rong Xiang2, Lina Wang3 and Pengpeng Qu5
1Department of Gynecology and Obstetrics, Tianjin First Center Hospital, Tianjin, China
2Department of Immunology, Nankai University School of Medicine, Tianjin, China
3State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences, Tianjin, China
4Department of Pathology, Tianjin First Center Hospital, Tianjin, China
5Department of Gynecology Oncology, Tianjin Central Hospital of Gynecology Obstetrics, Tianjin, China
*These authors have contributed equally to this work
Correspondence to:
Lina Wang, email: [email protected]
Pengpeng Qu, email: [email protected]
Keywords: PPA1, epithelial ovarian cancer, metastasis, Wnt/β-catenin
Received: January 18, 2017 Accepted: June 19, 2017 Published: July 18, 2017
ABSTRACT
Inorganic pyrophosphatase (PPA1) activity is a key determinant of cellular inorganic pyrophosphate levels, and its expression is correlated with growth of several solid tumors. To investigate this relationship, we first examined PPA1 expression in human epithelial ovarian cancer (EOC) samples, and found that PPA1 was overexpressed in tumors from EOC patients. Higher PPA1 levels correlated with advanced grades, stages, and poor survival in EOC patients. Examination of PPA1 function in EOC revealed that silencing PPA1 inhibited EOC migration, epithelial-mesenchymal transition (EMT), and metastasis in vitro and in vivo. In addition, PPA1 may promote the dephosphorylation and translocation of β-catenin. These results demonstrate that silencing PPA1 inhibits EOC metastasis by suppressing the Wnt/β-catenin signaling pathway. Strategies for downregulating PPA1 may have therapeutic potential for the prevention and treatment of EOC.